SuspendedPhase 2NCT04616560
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Damon R ReedPediatric Early Phase Clinical Trial Network
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 77 target
- Eligibility
- 12-39 years · All sexes
- Timeline
- 2021 – 2027
Study locations (28)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04616560 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.
- RECRUITINGPHASE1, PHASE2NCT06892678DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05660408RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid TumorsUniversity of Florida